Tag: Johnson & Johnson

Johnson & Johnson Institute opened a new facility in China

The Johnson & Johnson Institute, a leader in professional medical education, announced the opening of its new facility in Beijing. It represents the largest investment in the global relaunch of the Johnson & Johnson institutes.

Janssen Biotech will buy BeneVir Biopharm

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.

Johnson & Johnson Innovation creates a research incubator in Belgium

test tubes
The Belgium-based JLINX incubator – a collaboration launched in March 2016 between Janssen Pharmaceutica NV and Bioqube Ventures – will become part of the global Johnson & Johnson Innovation network

Johnson & Johnson launches its innovation hub in China

johnson & johnson
Johnson & Johnson Innovation announced a collaboration with the Shanghai Municipal Government and Shanghai Pharma Engine Company Ltd

Janssen and Zymeworks become partners in drug development

drug development
Zymeworks Inc announced it has executed a licensing agreement with Janssen Biotech

Johnson & Johnson sets up partnering office at Seoul Bio Hub

Global pharmaceutical and biohealth firm Johnson & Johnson opened a new partnering office in Seoul to support emerging entrepreneurs and biotech businesses

Janssen localizes the manufacturing of Imbruvik in Russia

janssen j&j
Janssen confirmed its intention to localize the portfolio of innovative drugs for the treatment of malignant blood diseases, including the localization of Imbruvik

Johnson & Johnson set up partnership with Indian Microbial Technology Institute

Johnson & Johnson Private Limited announced a new partnership with the Institute of Microbial Technology to unlock the potential of Indian science and help accelerate the discovery of innovative new treatments for tuberculosis

Johnson & Johnson reported about promising clinical data for HIV vaccine

Johnson & Johnson today announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies

EU Commission authorized Johnson & Johnson’s acquisition of Actelion

As Johnson & Johnson’s proposal hit the news earlier this year in January, the company signed an acquisition agreement with Actelion Pharmaceuticals